Neurology Volume 66(2) Supplement 1 January 24, 2006

Inclusion-body myositis: Clinical and pathologic aspects, and basic research potentially relevant to treatment.
Askanas, Valerie MD, PhD; Dalakas, Marinos C. MD; Engel, W King MD

2
pg. S1-S6
A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes.
Finch, Caleb E. PhD

3
pg. S7-19
The ubiquitin proteolytic system: From a vague idea, through basic mechanisms, and onto human diseases and drug targeting.
Ciechanover, Aaron MD, DSc

4
pg. S20-S29
Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects.
Engel, W King MD; Askanas, Valerie MD, PhD

5
pg. S30-S32
The current status of treatment for inclusion-body myositis.
Griggs, Robert C. MD, FAAN

6
pg. S33-S38
Inflammatory, immune, and viral aspects of inclusion-body myositis.
Dalakas, Marinos C. MD

[Articles]

7
pg. S39-S48
Inclusion-body myositis: A myodegenerative conformational disorder associated with A[beta], protein misfolding, and proteasome inhibition.
Askanas, Valerie MD, PhD; Engel, W King MD

8
pg. S49-S55
Mitochondrial abnormalities in inclusion-body myositis.
Oldfors, A MD, PhD; Moslemi, A R. PhD; Jonasson, L; Ohlsson, M MD; Kollberg, G MSc; Lindberg, C MD, PhD
Controlling autoimmunity in sporadic inclusion-body myositis.
Steinman, Lawrence MD

Immunotherapeutic relief from persistent infections and amyloid disorders.
McGavern, Dorian B. PhD

Inclusion-body myositis and Alzheimer disease: Two sides of the same coin, or different currencies altogether?
Murphy, M Paul PhD; Golde, Todd E. MD, PhD

Amyloidogenic processing of [beta]-amyloid precursor protein in intracellular compartments.
Vetrivel, Kulandaivelu S. PhD; Thinakaran, Gopal PhD

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis.
Glabe, Charles G. PhD; Kayed, Rakez PhD

Apolipoprotein E and Alzheimer disease.
Huang, Yadong MD, PhD

Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies.
van Leeuwen, F W. PhD; van Tijn, P MSc; Sonnemans, M A.F. BSc; Hobo, B BSc; Mann, D M.A. PhD; Van Broeckhoven, C PhD; Kumar-Singh, S MD, PhD; Cras, P MD, PhD; Leuba, G PhD; Savioz, A PhD; Maat-Schieman, M L.C. MD, PhD; Yamaguchi, H MD, PhD; Kros, J M. MD, PhD; Kamphorst, W MD, PhD; Hol, E M. PhD; de Vos, R A.I. MD; Fischer, D F. PhD
Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases. 
Davies, Kelvin J.A. PhD, DS; Shringarpure, Reshma PhD

Brain and brawn: Parallels in oxidative strength.
Moreira, P I. MA; Honda, K MD, PhD; Zhu, X PhD; Nunomura, A MD, PhD; Casadesus, G PhD; Smith, M A. PhD; Perry, G PhD

Zhang, Kezhong PhD; Kaufman, Randal J. PhD

Treatment and prevention of the amyloidoses: Can the lessons learned be applied to sporadic inclusion-body myositis?
Buxbaum, Joel N. MD

RNA interference as potential therapy for neurodegenerative disease: Applications to inclusion-body myositis?
Paulson, Henry MD, PhD

Developing therapeutics for the diseases of protein misfolding.
May, Barnaby C.H. PhD; Govaerts, Cedric PhD; Cohen, Fred E. MD, PhD

Pilot trial of etanercept in the treatment of inclusion-body myositis.
Barohn, R J. MD; Herbelin, L BS; Kissel, J T. MD; King, W PT; McVey, A L. MD; Saperstein, D S. MD; Mendell, J R. MD